Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:7/1/2015)... , July 1, 2015 OncoSec Medical Inc. ("OncoSec") ... immunotherapies, today announced that CEO and President Punit Dhillon ... the Company,s listing to The Nasdaq Stock Market at 9:30 ... in New York City .   ... and stakeholders, we are honored to open the Nasdaq to ...
(Date:7/1/2015)... PISCATAWAY, New Jersey , July 1, 2015 ... Centre (CCDC) celebrates 50 years of the Cambridge ... the launch of new software in the CSD-System ... the world,s most comprehensive collection of crystal structure ... interaction analysis, geometry analysis, and support for tailored ...
(Date:6/30/2015)... SANTA MONICA, Calif. , June 30, 2015 /PRNewswire/ ... th consecutive year, is an event dedicated to ... on the hottest issues and topics affecting the industry ... designed to address the challenges and opportunities facing today,s ... For more information and to register for MEDevice San ...
Breaking Medicine Technology:OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 2OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 3Scientific Symposium and New Software for Crystallographers and Scientists Worldwide to Celebrate 50 Years of the Cambridge Structural Database 2Scientific Symposium and New Software for Crystallographers and Scientists Worldwide to Celebrate 50 Years of the Cambridge Structural Database 3MEDevice San Diego 2015 Attracts High-Tech Medical Industry 2
... ARBOR, Mich., Aug. 6 Terumo Heart, Inc. ... Left Ventricular Assist,System (LVAS) took place on July ... Ann Arbor, Michigan. The surgery was performed by,Francis ... U.S. Pivotal Trial. DuraHeart is the world,s first ...
... held on Wednesday, August 6, 2008 at 8:00 ... ... Isolagen(TM), Inc. (Amex:,ILE) announced today positive top-line efficacy and safety results from ... for the treatment of nasolabial folds, or wrinkles.,Each study, conducted under an ...
Cached Medicine Technology:First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial 2Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® will team ... America (HCA), as it further expands its Strategic Alliance Partnership Program for raising ... new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah Cannon to ...
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show hosted ... 11, 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event ... petting zoo, an Elvis impersonator, a silent auction and concessions. , Horses and riders ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... author Lisa Stolzenberg, a Professor in FIU’s School of International and Public Affairs. ... 17 years who participated in the National Survey on Drug Use and Health, ...
(Date:7/1/2015)... ... 2015 , ... Element Blue ™, a leading IT ... has received trademark protection for its SensorInsight® computer software platform. SensorInsight® is used ... sources providing an environment where users can view and compare real-time and historic ...
(Date:7/1/2015)... ... July 01, 2015 , ... Bunion Bootie, the newest and ... two or more Bunion Booties directly from their website, http://www.BunionBootie.com can ... misaligned toes and its ultra thin properties allow for protection against rubbing footwear ...
Breaking Medicine News(10 mins):Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2
... Researchers from MetroHealth Medical Center and Case Western Reserve ... who have had previous spontaneous preterm births with 17 ... another preterm birth would consequently reduce both short-term and ... year. The results of their study are reported in ...
... medication labels in languages other than English, few New ... limited-English patients face serious risk of medication error, according ... Medicine presented today at the annual meeting of the ... ,"Imagine, as an English speaker, picking up ...
... out of three sexually active older adults infected with HIV ... researchers//. A survey of 260 HIV-positive older adults found that ... were in a relationship. ,AIDs cases among the ... for Disease Control and Prevention, they will account for half ...
... the potential for medication errors, says a new study by ... May issue of the journal Medical Care. ,The ... College of Pharmacy professor Daniel C. Malone, Ph.D., who is ... Research on Therapeutics at the Critical Path Institute. ...
... for their antiretroviral medications experienced interruptions in drug ... logistical disruptions. These treatment interruptions led to the ... ,These findings by a team led ... Makerere University, Kampala, and UCSF are reported in ...
... of global warming keeps coming up from across the world. ... seawaters are killing marine life in their thousands. ... ago it was reported that a Norwegian glacier had shrunk ... a usually frozen fjord (a long narrow arm of ...
Cached Medicine News:Health News:Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs 2Health News:Many NYC Pharmacies Fail to Translate Prescription Labels for Patients Who Don't Understand English 2Health News:Many NYC Pharmacies Fail to Translate Prescription Labels for Patients Who Don't Understand English 3Health News:One-Third of Sexually Active Older Adults With HIV/AIDs Has Unprotected Sex 2Health News:Pharmacists' Workload Contributes To Errors 2Health News:Resistance to Anti-HIV Drugs in Uganda Developed Due to Drug Supply Problems 2Health News:Norwegian Glacier Shrinks and Marine Life Poisoned as the Globe Warms 2Health News:Norwegian Glacier Shrinks and Marine Life Poisoned as the Globe Warms 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: